FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1620592016> ?p ?o ?g. }

• W1620592016 abstract "Abstract Introduction: Patients with acute myeloid leukemia (AML) characterized by FMS-like tyrosine kinase-3 (FLT-3) internal tandem duplication (ITD) mutations have poor outcomes, especially in the relapsed setting. Although small molecule inhibitors of FLT-3 have been explored for these patients, many inhibitors have demonstrated limited single-agent efficacy with short response durations. Sorafenib, a multi-kinase inhibitor with activity against FLT-3, has previously been evaluated alone and in combination with induction chemotherapy or azacytidine in AML patients. Here we describe our experience with the combination of the DNA hypomethylating agent, decitabine (D), and sorafenib (S) for the treatment of FLT-3 ITD mutant AML. Methods: We retrospectively reviewed records of patients with FLT-3 ITD mutant AML who were treated off protocol with decitabine and sorafenib from 2011-present. Descriptive statistics, treatment response, and overall survival were recorded. Results: A total of six patients were identified. Mean age was 56 (range 34-70) years. Two-thirds (4/6) were female. All patients were confirmed to have recurrence of de novo AML characterized by FLT-3 ITD mutations prior to therapy. Patients received at least 1-2 cycles of concurrent decitabine 20 mg/m2 for 10 days and sorafenib 200-400 mg twice a day for 28 days. Five patients had relapsed/refractory AML (RR-AML) following 1-3 prior therapies. One patient had de novo AML in complete remission with incomplete count recovery (CRi) and received DS as consolidation. The overall response rate was 83%. Eighty percent (4/5) of patients with RR-AML attained CRi. One patient receiving DS consolidation attained complete remission (CR). Two patients received subsequent allogeneic stem cell transplantation with one individual still alive after 348 days. FLT3 ITD allelic ratio (available on 3 patients) decreased after DS therapy and correlated with CRi. Median overall survival was 111 days (range 59-348) from the initiation of DS to death from any cause or last known follow-up. Two patients developed treatment-related neutropenic fever/sepsis and elevated liver enzymes, respectively, which did not require dose adjustment. One patient developed heart failure of uncertain etiology. Conclusions: In this single institute case series, we demonstrated that the combination of decitabine (10 days) and sorafenib was well tolerated, resulted in high CR/CRi rates (80%), and prolonged overall survival in patients with heavily pretreated relapsed/refractory FLT-3 ITD mutant AML. Further investigation of this regimen in clinical trials is warranted. Table 1: Case series Patient Age(years) Sex No. of Prior therapies PriorAlloSCT * Blasts Prior to DS (%) No. of DSCycles Responseto therapy Overall survival (Days) 1 54 Female 3 N BM 70% 1 CRi 141 2 70 Female 1 N PB 53% 2 CRi 82 3 64 Male 1 N BM 68% 2 CRi 62 4 60 Male 1 N BM 2% 1 CR 198 5 34 Female 3 Y PB 48% 1 NR 348 6 58 Female 3 Y NA 2 CRi 59 Figure 1 Figure 1. *Allogeneic stem cell transplantation Disclosures Off Label Use: We are going to discuss the use of decitabine and sorafenib combination in relapsed/refractory FLT3 mutant AML. Decitabine is a DNA hypomethylating agent and sorafenib is a multikinase inhibitor, both of which have been evaluated individually in AML patients.." @default.
• W1620592016 created "2016-06-24" @default.
• W1620592016 creator A5006394357 @default.
• W1620592016 creator A5038660651 @default.
• W1620592016 creator A5039028985 @default.
• W1620592016 creator A5040198845 @default.
• W1620592016 creator A5046140518 @default.
• W1620592016 creator A5051165777 @default.
• W1620592016 creator A5060452476 @default.
• W1620592016 date "2014-12-06" @default.
• W1620592016 modified "2023-09-30" @default.
• W1620592016 title "Decitabine and Sorafenib Therapy in Patients with FLT3-ITD Mutant Acute Myeloid Leukemia Is Associated with High Response Rates—a Single Institute Experience" @default.
• W1620592016 doi "https://doi.org/10.1182/blood.v124.21.5284.5284" @default.
• W1620592016 hasPublicationYear "2014" @default.
• W1620592016 type Work @default.
• W1620592016 sameAs 1620592016 @default.
• W1620592016 citedByCount "4" @default.
• W1620592016 countsByYear W16205920162019 @default.
• W1620592016 countsByYear W16205920162020 @default.
• W1620592016 countsByYear W16205920162021 @default.
• W1620592016 crossrefType "journal-article" @default.
• W1620592016 hasAuthorship W1620592016A5006394357 @default.
• W1620592016 hasAuthorship W1620592016A5038660651 @default.
• W1620592016 hasAuthorship W1620592016A5039028985 @default.
• W1620592016 hasAuthorship W1620592016A5040198845 @default.
• W1620592016 hasAuthorship W1620592016A5046140518 @default.
• W1620592016 hasAuthorship W1620592016A5051165777 @default.
• W1620592016 hasAuthorship W1620592016A5060452476 @default.
• W1620592016 hasConcept C104317684 @default.
• W1620592016 hasConcept C126322002 @default.
• W1620592016 hasConcept C143998085 @default.
• W1620592016 hasConcept C150194340 @default.
• W1620592016 hasConcept C190727270 @default.
• W1620592016 hasConcept C2776239401 @default.
• W1620592016 hasConcept C2778019345 @default.
• W1620592016 hasConcept C2778041864 @default.
• W1620592016 hasConcept C2778695046 @default.
• W1620592016 hasConcept C2778729363 @default.
• W1620592016 hasConcept C2780235182 @default.
• W1620592016 hasConcept C54355233 @default.
• W1620592016 hasConcept C71924100 @default.
• W1620592016 hasConcept C86803240 @default.
• W1620592016 hasConceptScore W1620592016C104317684 @default.
• W1620592016 hasConceptScore W1620592016C126322002 @default.
• W1620592016 hasConceptScore W1620592016C143998085 @default.
• W1620592016 hasConceptScore W1620592016C150194340 @default.
• W1620592016 hasConceptScore W1620592016C190727270 @default.
• W1620592016 hasConceptScore W1620592016C2776239401 @default.
• W1620592016 hasConceptScore W1620592016C2778019345 @default.
• W1620592016 hasConceptScore W1620592016C2778041864 @default.
• W1620592016 hasConceptScore W1620592016C2778695046 @default.
• W1620592016 hasConceptScore W1620592016C2778729363 @default.
• W1620592016 hasConceptScore W1620592016C2780235182 @default.
• W1620592016 hasConceptScore W1620592016C54355233 @default.
• W1620592016 hasConceptScore W1620592016C71924100 @default.
• W1620592016 hasConceptScore W1620592016C86803240 @default.
• W1620592016 hasLocation W16205920161 @default.
• W1620592016 hasOpenAccess W1620592016 @default.
• W1620592016 hasPrimaryLocation W16205920161 @default.
• W1620592016 hasRelatedWork W103524613 @default.
• W1620592016 hasRelatedWork W1982432067 @default.
• W1620592016 hasRelatedWork W2008001245 @default.
• W1620592016 hasRelatedWork W2070609585 @default.
• W1620592016 hasRelatedWork W2204648307 @default.
• W1620592016 hasRelatedWork W2212892079 @default.
• W1620592016 hasRelatedWork W2546651944 @default.
• W1620592016 hasRelatedWork W2552548149 @default.
• W1620592016 hasRelatedWork W2556747587 @default.
• W1620592016 hasRelatedWork W2557135655 @default.
• W1620592016 hasRelatedWork W2557529932 @default.
• W1620592016 hasRelatedWork W2563543355 @default.
• W1620592016 hasRelatedWork W2566888040 @default.
• W1620592016 hasRelatedWork W2575877163 @default.
• W1620592016 hasRelatedWork W2591121872 @default.
• W1620592016 hasRelatedWork W2593528853 @default.
• W1620592016 hasRelatedWork W2903963474 @default.
• W1620592016 hasRelatedWork W2979327768 @default.
• W1620592016 hasRelatedWork W2979459516 @default.
• W1620592016 hasRelatedWork W918891332 @default.
• W1620592016 isParatext "false" @default.
• W1620592016 isRetracted "false" @default.
• W1620592016 magId "1620592016" @default.
• W1620592016 workType "article" @default.